KAEL Gem-Vax posts promising NSCLC data; India expects vaccine market to soar;

> South Korea-based KAEL Gem-Vax, which we profiled in our report on promising pancreatic cancer drugs, has reported Phase II results of its GV1001 vaccine for Stage III non-small cell lung cancer. The company found GV1001 was well tolerated, immunizing the majority of NSCLC patients and establishing durable T-cell memory. A randomized trial is next. KAEL Gem-Vax release

> The Indian vaccine market is expected to grow 23% during 2011-2012, reaching $4.6 billion in revenue by 2017. Report

> Experts at the U.K.'s National Health Service are weighing whether they should recommend that all kids under 17 should get the flu shot. Report

> A vaccine injected directly into a pancreatic tumor could hold promise for patients whose cancer can't be surgically removed. The Phase I trial, which included just 6 patients, was conducted at the Cancer Institute of New Jersey. Article

And Finally... A new web-based reporting system could make vaccines more effective by speeding the data collection process following vaccination. Article

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.